BDXBecton Dickinson & Co.

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Thomas E. Polen

Location

New Jersey, USA

Exchange

NYSE

Website

https://bd.com

Summary

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public.

Company Info

CEO

Thomas E. Polen

Location

New Jersey, USA

Exchange

NYSE

Website

https://bd.com

Summary

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public.

AI Insights for BDX
6 min read

Quick Summary

Becton, Dickinson and Company, known as BD, is a U.S.-based medical technology company headquartered in Franklin Lakes, New Jersey. The company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products used across healthcare and life sciences markets. Its customers include hospitals, healthcare systems, physicians, nurses, clinical laboratories, life science researchers, pharmaceutical companies, public health organizations, and in some cases consumers managing chronic conditions such as diabetes. BD’s business is heavily tied to recurring demand for consumable medical products, including syringes, catheters, specimen collection products, and vascular access devices. The company has historically operated through areas such as BD Medical, BD Life Sciences, and BD Interventional, although recent portfolio actions are refocusing the company more directly around MedTech. Its scale, global distribution, large installed base, and broad product portfolio make it a major supplier to healthcare institutions worldwide.

Strengths

•

BD’s primary strength is its scale as a global medical technology supplier with deep relationships across hospitals, laboratories, healthcare systems, and research organizations.

•

The company sells many products that are essential to routine healthcare delivery, which supports recurring demand and provides a degree of resilience across economic cycles.

•

Its product portfolio includes critical categories such as syringes, catheters, vascular access products, specimen collection products, and interventional devices.

•

BD also benefits from market leadership, a large installed base, manufacturing know-how, regulatory experience, and a long operating history.

•

The company’s low reported beta of 0.279 suggests the stock may be less volatile than the broader market, which can appeal to defensive investors.

Key Risks

•

BD faces risks from inflation, supply-chain disruption, higher financing costs, regulatory scrutiny, product recalls, and intense competition in the medtech and diagnostics industries.

•

Guidance reductions or further earnings estimate cuts could pressure the stock, especially because investor confidence has already been weakened by slower growth.

•

The spin-off and merger transaction with Waters creates execution risk, because BD must prove that the remaining company can grow faster and operate more efficiently as a more focused MedTech business.

•

Weakness in Life Sciences, soft demand in international markets, or lower hospital purchasing activity could reduce revenue momentum.

What to Watch

During the most recent reported period, BD generated operating revenue of about $4.983 billion, gross profit of about $2.315 billion, operating income of about $663 million, and net income of about $377 million.
Reported diluted EPS was $1.37, while the broader news flow referenced adjusted EPS results that beat expectations but still declined year over year.
The company continued to face investor scrutiny over modest revenue growth, margin performance, and weakness in Life Sciences.
A major strategic event was the completion of the spin-off of BD’s Biosciences and Diagnostic business and its merger with Waters, with BD receiving $4 billion intended for $2 billion of buybacks and $2 billion of debt reduction.
BD shareholders also received 0.135 Waters shares per BD share and are expected to own 39.2% of the combined Waters-related entity.
The transaction was designed to refocus BD as a more streamlined MedTech company, although the stock fell sharply around the event and some research outlets maintained cautious or negative ratings.

Price Drivers

•

BDX’s stock price is being driven by a mix of earnings expectations, revenue growth trends, portfolio restructuring, guidance revisions, and investor sentiment toward defensive healthcare stocks.

•

Recent reports show that revenue growth has been modest, with one cited quarter showing revenue up only 1.6% year over year while adjusted EPS declined 15%, even though EPS beat estimates.

•

Guidance has been an important negative driver because fiscal 2026 EPS guidance of $12.35 to $12.65 was reported below the $14.84 consensus, causing estimate cuts and weaker analyst sentiment.

•

The stock has also reacted to the spin-off of the Biosciences and Diagnostic business and merger with Waters, because investors are weighing the value of the separation against near-term disruption and lower growth visibility.

•

Valuation metrics such as a high reported price-to-earnings ratio, EV/EBITDA near 14.2, and dividend yield near 2.2% also influence whether investors view the shares as defensive value or as a slow-growth medtech name.

•

Broader market conditions, interest rates, inflation, healthcare spending, and investor preference for quality dividend stocks also affect BDX’s multiple and demand from long-term shareholders.

Recent News

•

Recent news around BD has been dominated by earnings performance, guidance concerns, analyst ratings, and the company’s portfolio restructuring.

•

One report noted that BD shares fell after weak revenue growth, even though earnings beat expectations, with Kovitz viewing the selloff as an overreaction and adding to its position.

•

Another update highlighted fiscal Q1 adjusted EPS of $2.91, which beat estimates but declined 15% year over year, while revenue rose 1.6% to $5.25 billion.

•

Guidance for fiscal 2026 EPS of $12.35 to $12.65 was reported below consensus, contributing to falling estimates and a Zacks Sell rating.

•

BD also completed the spin-off of its Biosciences and Diagnostic business and merger with Waters, receiving $4 billion for planned buybacks and debt reduction.

•

Other commentary has framed BD as a durable dividend stock and medical-device leader with recurring revenue, margin expansion potential, and possible value creation from its strategic separation.

Market Trends

•

BD is affected by several broad market trends, including aging populations, rising chronic disease, increased demand for healthcare procedures, and greater emphasis on hospital efficiency.

•

Medtech companies are benefiting from long-term demand for devices and consumables, but they are also facing inflation, supply-chain constraints, wage pressure, and higher financing costs.

•

Investors have recently favored companies with strong earnings visibility, durable cash flows, and defensive characteristics, which can help BD, but they have also punished firms with weak guidance or slow organic growth.

•

The healthcare market is seeing continued portfolio reshaping, spin-offs, and mergers as companies try to improve strategic focus and unlock shareholder value.

•

Dividend stocks and Dividend Kings have attracted attention from investors seeking stability outside high-growth AI and technology trades.

•

At the same time, regulatory complexity, hospital budget pressure, global competition, and changing diagnostic demand remain important headwinds for the broader medical equipment and healthcare tools sector.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on BDX

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

avatar
@AlexWalker 1 month ago

Which Dividend Stocks Can Weather a Downturn?

Which Dividend Stocks Can Weather a Downturn?

When the market gets shaky, I like the idea of having businesses that can keep generating cash and paying dividends through the cycle. Healthcare names such as , and stand out because demand for their products doesn’t disappear when the economy slows.

I’m curious, would you rather focus on dividend stability or higher growth during a downturn?

avatar
@ReaderMed143 11 months ago

Medical Tech Staple $BDX Adds to Dividend Streak

Medical Tech Staple $BDX Adds to Dividend Streak

Becton Dickinson bumped up its payout once more, keeping alive a steady run of reliable returns. This quiet player in med-tech doesn't grab headlines, yet always shows up. 

Instead of flash, it offers stability perfect for those who value predictability. So far, BDX keeps giving solid reasons to stay in conservative portfolios.

avatar
@DamnRay 1 year ago

Becton, Dickinson & Co declares $1.04/share quarterly dividend

Becton, Dickinson & Co declares $1.04/share quarterly dividend

  had announced a quarterly dividend of $1.04 per common share, payable September 30, 2025, to shareholders of record September 8. The company has been doing good in healthcare equipment sector.

avatar
@MoneyMaker23 1 year ago

Becton, Dickinson and Company just declared its dividend

Becton, Dickinson and Company just declared its dividend

which is a medical technology company, just declared a quarterly cash dividend of $1.04 per share, payable on September 30. The company has paid dividends consistently and seems like a good choice in the health sector.

No more topics to show